Literature DB >> 6692632

Tinidazole pharmacokinetics in severe renal failure.

R A Robson, R R Bailey, J R Sharman.   

Abstract

The single-dose pharmacokinetics of intravenously and orally administered tinidazole were studied in normal subjects and patients with severe chronic renal failure. The clearance of tinidazole was also measured in patients on regular haemodialysis. After intravenous administration the mean elimination half-life of tinidazole was 17.1 +/- 2.3 (SD) hours in the normal subjects and 16.9 +/- 4.9 hours in patients with renal failure; the mean apparent volumes of distribution were 0.80 +/- 0.09 L/kg and 0.69 +/- 0.09 L/kg, respectively. Following oral administration the mean elimination half-life was 15.6 +/- 1.6 hours in the normal subjects and 18.4 +/- 3.5 hours in patients with renal failure; there were no statistically significant differences in these pharmacokinetic parameters. There was no accumulation of the major metabolite (hydroxymethyl tinidazole) in normal subjects or in patients with renal failure. Tinidazole clearance during haemodialysis was 71 +/- 7.7 ml/min. In the presence of renal failure no modification of tinidazole dosage would appear to be necessary. Tinidazole should be administered in full dosage following haemodialysis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692632     DOI: 10.2165/00003088-198409010-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  5 in total

1.  Treatment of trichomonal vaginitis with a single dose of tinidazole.

Authors:  A Weidenbach; H Leix
Journal:  Curr Med Res Opin       Date:  1974       Impact factor: 2.580

2.  Bile and serum levels of tinidazole after a single oral dose.

Authors:  P S Hunt; A J Davidson; J Alden; S Cheng
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

3.  Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy.

Authors:  P R Sawyer; R N Brogden; R M Pinder; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

4.  Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis.

Authors:  B L Flouvat; C Imbert; D M Dubois; B P Temperville; A F Roux; G C Chevalier; G Humbert
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

5.  Liquid chromatographic assay for metronidazole and tinidazole: pharmacokinetic and metabolic studies in human subjects.

Authors:  I Nilsson-Ehle; B Ursing; P Nilsson-Ehle
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

  5 in total
  5 in total

1.  Penetration of tinidazole into skin blister fluid following its oral administration.

Authors:  A Klimowicz; A Nowak; S Bielecka-Grzela
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

4.  Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.

Authors:  Xue-Qing Li; Anders Björkman; Tommy B Andersson; Lars L Gustafsson; Collen M Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

Review 5.  Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents.

Authors:  Valentin Al Jalali; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.